2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.

2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.

ID: 147727

(firmenpresse) - HONG KONG -- (Marketwire) -- 05/17/12 -- Today, announced new reports highlighting Acorda Therapeutics Inc (NASDAQ: ACOR) and Pharmacyclics, Inc. (NASDAQ: PCYC). Gain market insight with full analysis and research downloads available at .

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Acorda Therapeutics Inc for its current position within the healthcare industry. Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. The full research report on Acorda Therapeutics Inc (NASDAQ: ACOR) is available here: .

Brighton Markets has released research on Pharmacyclics, Inc. for its changing role within the healthcare industry. Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. The full research report on Pharmacyclics, Inc. (NASDAQ: PCYC) is available here: .





About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.



Contact:

Jean Barnes


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  2012 Economic Outlook - Report Highlights Stage Stores Inc and TriMas Corp Guardian Equity Management and Catalyst Property Solutions Form a Joint Venture
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 17.05.2012 - 13:00 Uhr
Sprache: Deutsch
News-ID 147727
Anzahl Zeichen: 0

contact information:
Town:

HONG KONG



Kategorie:

Investment Services & Trading



Diese Pressemitteilung wurde bisher 225 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von

Brighton Markets (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Brighton Markets



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z